MEDICLIN AI Stock Analysis
Want to see DE:MED full AI Analyst Report?
MEDICLIN (MED) AI Stock Analysis
MEDICLIN
(XETRA:MED)
The overall score of 53 reflects a high-risk profile. The primary concern is the severe operational disruption evidenced by collapsing gross margins and revenue, which overshadows the company's positive cash flow and improving balance sheet. While the stock's technical trend is modestly positive and the valuation appears low, these factors are likely a consequence of the market's deep uncertainty about the company's ability to restore sustainable profitability.
MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 249.38M
- Dividend Yield
- 0.76%
- Average Volume (3M)
- 6,009
- Price to Earnings (P/E)
- 8.0
- Beta (1Y)
- 0.31
- Revenue Growth
- 0.77%
- EPS Growth
- -11.41%
- Country
- Germany
- Employees
- 7,048
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
MEDICLIN Business Overview & Revenue Model
Company Description
Mediclin AG is a German healthcare enterprise primarily engaged in managing hospitals across the nation. Its operations are categorized into three main segments: Post-Acute, Acute, and various other related activities. The company offers a comprehens...
How the Company Makes Money
MEDICLIN makes money primarily by operating healthcare facilities and charging for patient services delivered in its hospitals, rehabilitation clinics, and nursing care facilities. Key revenue streams typically include (1) payments for acute inpatien...
MEDICLIN Financial Statement Overview
Summary
Financial performance is highly polarized. Cash flow generation is a relative strength, and the balance sheet shows improving leverage. However, these positives are severely undermined by a catastrophic collapse in gross margins and a 45.3% revenue decline in the TTM period, indicating a fundamental operational disruption that questions earnings sustainability.
Income Statement
35NegativeBalance Sheet
45NeutralCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 783.49M | 784.49M | 748.80M | 730.10M | 704.70M | 673.10M |
| Gross Profit | -27.87M | 113.81M | 623.00M | 594.60M | 571.90M | 551.00M |
| EBITDA | 103.33M | 98.66M | 106.39M | 101.26M | 91.80M | 85.43M |
| Net Income | 31.06M | 25.49M | 24.84M | -10.78M | 9.44M | 1.46M |
Balance Sheet | ||||||
| Total Assets | 866.81M | 879.69M | 905.91M | 880.50M | 916.11M | 881.24M |
| Cash, Cash Equivalents and Short-Term Investments | 178.00M | 72.18M | 107.56M | 115.29M | 88.04M | 133.48M |
| Total Debt | 381.62M | 390.83M | 464.13M | 479.82M | 502.67M | 439.96M |
| Total Liabilities | 586.15M | 630.06M | 683.17M | 684.47M | 706.79M | 698.22M |
| Stockholders Equity | 279.75M | 248.95M | 222.51M | 195.92M | 209.21M | 183.28M |
Cash Flow | ||||||
| Free Cash Flow | 48.60M | 51.44M | 35.88M | 40.43M | 8.62M | 64.96M |
| Operating Cash Flow | 91.91M | 99.87M | 80.57M | 78.00M | 34.64M | 81.97M |
| Investing Cash Flow | -23.99M | -37.14M | -15.13M | -9.51M | -6.24M | -7.09M |
| Financing Cash Flow | -92.54M | -97.40M | -73.16M | -45.48M | -56.17M | -55.26M |
MEDICLIN Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Negative. The current price of 5.25 is below the 20-day moving average (MA) of 5.35, below the 50-day MA of 5.34, and above the 200-day MA of 4.32, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 46.97 is Neutral, neither overbought nor oversold. The STOCH value of 41.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MED.
MEDICLIN Peers Comparison
Overall Rating
DE:M1279Outperform
DE:LIK67Neutral
DE:RHK61Neutral
DE:MED53Neutral
DE:MAK27Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | EUR 343.70M | 17.93 | 16.58% | 6.14% | -27.50% | 13.64% | |
| 67Neutral | EUR 174.00M | 31.39 | 22.18% | 1.72% | 35.46% | 17.88% | |
| 61Neutral | EUR 984.00M | 22.97 | 3.16% | 1.36% | 3.54% | 11.21% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 53Neutral | EUR 249.38M | 7.98 | 11.94% | 0.76% | 0.77% | -11.41% | |
| 27Underperform | EUR 17.51M | -1.28 | 16.80% | ― | 2.73% | -1.80% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:MED | MEDICLIN AG | 5.25 | 1.85 | 54.28% | |
| DE:RHK | RHON-KLINIKUM AG | 14.70 | 2.89 | 24.49% | |
| DE:MAK | MATERNUS-Kliniken AG | 0.83 | -0.23 | -21.23% | |
| DE:LIK | Limes Schlosskliniken AG | 580.00 | 238.63 | 69.90% | |
| DE:JTH0 | Gesundheitswelt Chiemgau AG | 12.20 | 0.20 | 1.67% | |
| DE:M12 | M1 Kliniken AG | 19.54 | 4.19 | 27.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
